Page last updated: 2024-11-05

benzonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzonitrile is an organic compound with the formula C6H5CN. It is a colorless liquid with an almond-like odor. It is used as a solvent, a reagent in organic synthesis, and a precursor to other chemicals. Benzonitrile is produced industrially by the ammoxidation of toluene. It is a key intermediate in the production of pharmaceuticals, dyes, and other chemicals. Benzonitrile has been studied for its biological activity, such as its ability to inhibit the growth of bacteria and fungi. It is also a useful solvent for a variety of organic reactions. Benzonitrile is a relatively stable compound and can be stored for long periods of time.'

benzonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7505
CHEMBL ID15819
CHEBI ID27991
SCHEMBL ID6640
MeSH IDM0062835

Synonyms (64)

Synonym
LS-13256
benzoic acid nitrile
benzene, cyano-
wln: ncr
nsc-8039
nsc8039
benzenenitrile
c6h5-cn
CHEBI:27991 ,
NCGC00091747-01
ccris 3184
ai3-24184
benzenecarbonitrile
phenylcyanide
un2224
nsc 8039
hsdb 45
fenylkyanid [czech]
einecs 202-855-7
cyanobenzene
C09814
phenyl cyanide
100-47-0
benzonitrile
STK398186
benzonitrile, anhydrous, >=99%
B0082
MLS002454387
smr001372003
benzonitrile [un2224] [poison]
BMSE000284
CHEMBL15819
AKOS000120125
NCGC00091747-02
benzonitril
unii-9v9app5h5s
9v9app5h5s ,
fenylkyanid
ec 202-855-7
HMS3039F17
cas-100-47-0
tox21_302979
dtxsid7021491 ,
dtxcid001491
NCGC00256387-01
NCGC00259531-01
tox21_201982
FT-0622719
benzonitrile [hsdb]
benzonitrile [mi]
SCHEMBL6640
benzo nitrile
4-cyanobenzene
un 2224
J-000140
F1908-0163
benzonitrile, reagentplus(r), 99%
mfcd00001770
benzonitrile, for hplc, 99.9%
Q412567
AM10697
benzonitrile solvent
EN300-19362
Z104473628

Research Excerpts

Effects

ExcerptReferenceRelevance
"Benzonitriles have been evaluated as potential antiradiation agents in mice. "( [Radioprotective agents derived from benzonitrile].
Cassanas, G; Chapat, JP; Fatome, M; Fernandez, JP; Robbe, Y; Sentenac-Roumanou, H, 1986
)
1.99

Toxicity

ExcerptReferenceRelevance
"The herbicides dichlobenil (2,6-dichlorobenzonitrile), chlorthiamid (2,6-dichlorothiobenzamide) and their environmental degradation product 2,6-dichlorobenzamide are irreversibly bound and toxic to the olfactory mucosa following single injections in mice (Brandt et al."( Tissue-binding and toxicity of compounds structurally related to the herbicide dichlobenil in the mouse olfactory mucosa.
Brandt, I; Brittebo, E; Eriksson, C, 1992
)
0.55
" Structure-activity relationships indicate that for these compounds different mechanisms of toxic action are taking place dependent on the nature of the substituent."( Quantitative structure-activity study of the toxicity of benzonitriles to the ciliate Tetrahymena pyriformis.
Bryant, SE; Cronin, MT; Dearden, JC; Schultz, TW, 1995
)
0.54
" In the current study, we introduce a new Aβ toxicity inhibitor, SEN1500, which in addition to its block effect on Aβ1-42 toxicity in synaptophysin assays, can be administered orally and cross the blood-brain barrier without adverse effects in mice."( Dose-dependent improvements in learning and memory deficits in APPPS1-21 transgenic mice treated with the orally active Aβ toxicity inhibitor SEN1500.
Callaerts-Vegh, Z; D'Hooge, R; De Strooper, B; Lo, AC; Nerou, E; Scopes, DI; Tesseur, I; Treherne, JM; Vermaercke, B, 2013
)
0.39
" We observed high toxic effects of bromoxynil, chloroxynil, and ioxynil on both tested cell lines."( Study of Cytotoxic Effects of Benzonitrile Pesticides.
Demnerova, K; Grznarova, P; Knejzlik, Z; Lipov, J; Lovecka, P; Nindhia, TG; Ruml, T; Stiborova, H; Thimova, M, 2015
)
0.71

Pharmacokinetics

ExcerptReferenceRelevance
" Here, we describe the following: (1) the design, synthesis, and structure-activity relationship of a series of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives by in vitro studies of XO inhibitory activity in bovine milk and in vivo studies of serum uric acid (UA) reductive activity in rats, (2) a drug interaction study by a cytochrome P450 3A4 (CYP3A4) assay, and (3) a pharmacokinetic (PK) study."( Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors.
Ashizawa, N; Inoue, T; Iwanaga, T; Matsumoto, K; Nagata, O; Nakamura, H; Sato, T, 2009
)
0.35

Dosage Studied

The highest flexural and compressive strength was contributed by the PBGC-MWF4 with 2% dosage using a compound modifier. For benzonitrile in presence of DMSO, a clear dose-response of inhibition of tubulin assembly at 37 degrees C was seen.

ExcerptRelevanceReference
" For benzonitrile in presence of DMSO, a clear dose-response of inhibition of tubulin assembly at 37 degrees C was seen above the no-effect-concentration of 2 mM, with an IC(50) of 13 mM and protein denaturation starting above a level of about 20 mM."( Chromosomal genotoxicity of nitrobenzene and benzonitrile.
Böhm, KJ; Bolt, HM; Bonacker, D; Degen, GH; Stoiber, T; Thier, R; Unger, E, 2004
)
1.1
"We derive equations for the effective concentration giving 10% inhibition (EC10) with 95% confidence limits for probit (log-normal), Weibull, and logistic dose-response models on the basis of experimentally derived median effective concentrations (EC50s) and the curve slope at the central point (50% inhibition)."( Dose-response regressions for algal growth and similar continuous endpoints: calculation of effective concentrations.
Christensen, ER; Kusk, KO; Nyholm, N, 2009
)
0.35
" The highest flexural and compressive strength was contributed by the PBGC-MWF4 with 2% dosage using a compound modifier of dopamine hydrochloride and 3,4-dihydroxy benzonitrile, which were enhanced 61."( Surface-Treated Recycling Fibers from Wind Turbine Blades as Reinforcement for Waste Phosphogypsum.
Cui, N; Liu, Y; Wang, D; Yang, L; Zhao, W, 2022
)
0.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency60.26130.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency3.55330.000221.22318,912.5098AID743036; AID743042
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.91620.000229.305416,493.5996AID743069; AID743075; AID743077
aryl hydrocarbon receptorHomo sapiens (human)Potency7.07950.000723.06741,258.9301AID651777
gemininHomo sapiens (human)Potency1.83560.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID203473Binding constant against bovine serum albumin1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID343680Hexadecane-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1594609Drug reactivity against cysteine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID24226Partition coefficient (logP)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1134601Hydrogen-bond basicity, pKHB of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1594613Reversible drug reactivity against cysteine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID343682Hexadecane-water partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID1594614Reversible drug reactivity against serine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1331301n-Octanol/water partition coefficient, log P of the compound by HPLC method
AID23714Partition coefficient (logP)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID343398Octanol-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID23978Capacity ratio (log k'w)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID3436812,2,4-trimethylpentane-water partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID13312991-octanol/D2O distribution coefficient, log D of the compound at pH 7.4 by 1H NMR spectroscopic analysis
AID1134602Hexane-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1134599CHCl3-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1594610Drug reactivity against serine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (225)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (4.44)18.7374
1990's16 (7.11)18.2507
2000's82 (36.44)29.6817
2010's98 (43.56)24.3611
2020's19 (8.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.05 (24.57)
Research Supply Index5.44 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index127.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (74.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.31%)6.00%
Case Studies2 (0.87%)4.05%
Observational0 (0.00%)0.25%
Other224 (97.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]